Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.73 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035658 | 0.86 | KRAS (0.73) | KRAS | |
| SCHEMBL22036194 | 0.84 | KRAS (1.00) | KRAS | |
| SCHEMBL22035968 | 0.84 | KRAS (0.77) | KRAS | |
| SCHEMBL22035938 | 0.84 | KRAS (1.00) | KRAS | |
| SCHEMBL22036155 | 0.84 | KRAS (0.84) | KRAS | |
| SCHEMBL22036526 | 0.84 | KRAS (0.77) | KRAS | |
| SCHEMBL22035850 | 0.84 | KRAS (1.00) | KRAS | |
| SCHEMBL22035862 | 0.84 | KRAS (0.84) | KRAS | |
| SCHEMBL22035589 | 0.83 | KRAS (1.00) | KRAS | |
| SCHEMBL22035937 | 0.82 | KRAS (1.00) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406854-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | Umbra Therapeutics, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406854-A1 | COVALENT KRAS-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | KRAS, NRAS, HRAS | KRAS 1/4885IDO1 4798/4885 |
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KRAS 1/4885IDO1 4527/4885 |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885IDO1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.